

Luis E Raez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8459163/publications.pdf>

Version: 2024-02-01

187
papers

9,534
citations

108046

37
h-index

45040

94
g-index

188
all docs

188
docs citations

188
times ranked

13616
citing authors

#	ARTICLE	IF	CITATIONS
1	Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. <i>Oncologist</i> , 2022, , .	1.9	18
2	Challenges in Genetic Testing and Treatment Outcomes Among Hispanics With Lung Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 374-377.	1.4	3
3	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-“PD-(L)1 Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 1019-1028.	3.2	58
4	Reaching Across the Aisle: Cardio-Oncology Advocacy and Program Building. <i>Current Oncology Reports</i> , 2021, 23, 64.	1.8	11
5	EGFR L718V (+)/T790M (” as a Mechanism of Resistance in Patients with Metastatic Non-”small-cell Lung Cancer with EGFR L858R Mutations. <i>Clinical Lung Cancer</i> , 2021, 22, e817-e819.	1.1	4
6	“STK11“/“TP53“ co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9087-9087.	0.8	2
7	Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease. <i>Lung Cancer</i> , 2021, 155, 183-190.	0.9	8
8	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). <i>Immunotherapy</i> , 2021, 13, 727-734.	1.0	11
9	Characterization of KRAS Mutation Subtypes in Non-”small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2577-2584.	1.9	66
10	Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1165-1178.	1.5	20
11	Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1229-1235.	1.1	5
12	Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 192-198.	0.6	4
13	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662.	0.5	274
14	Neuregulin 1 Gene (NRG1). A Potentially New Targetable Alteration for the Treatment of Lung Cancer. <i>Cancers</i> , 2021, 13, 5038.	1.7	12
15	Influence of Sex in the Molecular Characteristics and Outcomes of Malignant Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 752918.	1.3	6
16	Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2021, 4, 1061-1071.	0.9	2
17	Complete Response of Primary Refractory ALK-Positive Large B-Cell Lymphoma Treated With Single-Agent Nivolumab. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e113-e117.	0.2	1
18	Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards. <i>Journal of Clinical Oncology</i> , 2020, 38, 633-644.	0.8	16

#	ARTICLE	IF	CITATIONS
19	Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP). <i>Thoracic Cancer</i> , 2020, 11, 353-361.	0.8	36
20	Lung Cancer in the Young. <i>Lung</i> , 2020, 198, 195-200.	1.4	32
21	Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. <i>Cancer Discovery</i> , 2020, 10, 1635-1644.	7.7	52
22	Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103033.	2.0	17
23	Florida Inter-Specialty Collaborative Project to Improve Cardio-Oncology Awareness and Identify Existing Knowledge Gaps. <i>JACC: CardioOncology</i> , 2020, 2, 535-538.	1.7	10
24	Scientific publications in cancer: in Latin America, strong scientific networks increase productivity (the TENJIN study). <i>Journal of Clinical Epidemiology</i> , 2020, 126, 1-8.	2.4	6
25	Lung Cancer Disparities in Hispanics: Molecular Diagnosis and Use of Immunotherapy. <i>JCO Global Oncology</i> , 2020, 6, 784-788.	0.8	15
26	Lung Cancer in Peru. <i>Journal of Thoracic Oncology</i> , 2020, 15, 891-898.	0.5	4
27	Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662093855.	1.0	8
28	Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location. <i>Oncology and Therapy</i> , 2020, 8, 59-66.	1.0	4
29	Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 385-390.	1.0	6
30	Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102978.	2.0	79
31	Anaphylactic Shock and Cardiac Arrest Secondary to Aprepitant. <i>American Journal of Therapeutics</i> , 2020, 27, e640-e642.	0.5	2
32	A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation. <i>Translational Lung Cancer Research</i> , 2020, 9, 2113-2119.	1.3	0
33	A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation. <i>Translational Lung Cancer Research</i> , 2020, 9, 2113-2119.	1.3	5
34	I.18-1 NTRK Fusion Proteins. <i>Journal of Thoracic Oncology</i> , 2019, 14, S1164-S1165.	0.5	0
35	Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 509-515.	1.4	16
36	I.13-1 New Technologies for Liquid Biopsies and Looking for Cost Effective Options for LATAM (RT-PCR, Tj ETQq0 0,0_rgBT /Oyerlock 10	0.5	0

#	ARTICLE	IF	CITATIONS
37	Inhibitor of Differentiation-1 Sustains Mutant <i>KRAS</i> -Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network. <i>Cancer Research</i> , 2019, 79, 625-638.	0.4	19
38	Molecular Epidemiology of <i>ALK</i> Rearrangements in Advanced Lung Adenocarcinoma in Latin America. <i>Oncology</i> , 2019, 96, 207-216.	0.9	24
39	The value of immunotherapy in head and neck cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 35-43.	1.4	14
40	RNA-based biomarker signatures in plasma as an independent predictor of outcome to chemotherapy in lung, colon, and breast cancers: Correlation of relative PD-L1 expression with immunotherapy outcomes.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14567-e14567.	0.8	1
41	Exosome-based detection of activating and resistance <i>EGFR</i> mutations from plasma of non-small cell lung cancer patients. <i>Oncotarget</i> , 2019, 10, 2911-2920.	0.8	35
42	Exploiting metabolic susceptibilities in glioblastoma via glycolytic inhibition and ketogenic therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13558-e13558.	0.8	1
43	Clinical responses and survival in Hispanic patients with non-small cell lung cancer treated with immunotherapy compared with non-Hispanic whites.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18109-e18109.	0.8	1
44	Effect of oligometastatic disease management with stereotactic body radiation therapy on survival in patients with metastatic lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13582-e13582.	0.8	1
45	Abstract 1518: Gene expression profile and gender differences related with immune processes in solid tumors. , 2019, , .		0
46	Efficacy of Larotrectinib in <i>TRK</i> Fusion-Positive Cancers in Adults and Children. <i>New England Journal of Medicine</i> , 2018, 378, 731-739.	13.9	2,036
47	The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments. <i>Lung Cancer</i> , 2018, 119, 7-13.	0.9	43
48	<i>EGFR</i> - <i>RAD51</i> Fusion: A Targetable Partnership Originated from the Tumor Evolution?. <i>Journal of Thoracic Oncology</i> , 2018, 13, e33-e34.	0.5	17
49	Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. <i>ESMO Open</i> , 2018, 3, e000344.	2.0	105
50	Making Sense of Immunotherapy in Lung Cancer: What the Pulmonologist Needs to Know?. <i>Current Pulmonology Reports</i> , 2018, 7, 42-48.	0.5	0
51	Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression. <i>Targeted Oncology</i> , 2018, 13, 175-187.	1.7	31
52	Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. <i>Biochemical and Biophysical Research Communications</i> , 2018, 500, 621-625.	1.0	44
53	Exosome-Based Detection of <i>EGFR</i> T790M in Plasma from Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 2944-2950.	3.2	157
54	Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 30-33.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Challenges in Lung Cancer Screening in Latin America. <i>Journal of Global Oncology</i> , 2018, 4, 1-10.	0.5	15
56	Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1076-S1080.	0.6	5
57	Detection of epidermal growth factor receptor mutations in circulating tumor DNA: reviewing BENEFIT clinical trial. <i>Journal of Thoracic Disease</i> , 2018, 10, 6388-6391.	0.6	5
58	Old myths about old patients: the case of non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S362-S363.	1.3	0
59	Pneumonitis in Patients with Lung Cancer Following Treatment: the Effects of Chemotherapy, Immunotherapy, and Tyrosine Kinase Inhibitors. <i>Current Pulmonology Reports</i> , 2018, 7, 214-219.	0.5	0
60	Tumor Type-Agnostic Treatment and the Future of Cancer Therapy. <i>Targeted Oncology</i> , 2018, 13, 541-544.	1.7	7
61	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1248-1268.	0.5	515
62	Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. <i>JAMA Oncology</i> , 2018, 4, 1430.	3.4	2
63	ROS-1 Rearrangements in Circulating Tumor Cells. <i>Journal of Thoracic Oncology</i> , 2018, 13, e71-e72.	0.5	9
64	Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9036-9036.	0.8	15
65	Use of cell-free circulating RNA (cfRNA) levels in plasma and expression of HER2 and PD-L1 to monitor disease status in metastatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15013-e15013.	0.8	1
66	Lung cancer immunotherapy outcomes in Hispanic patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18665-e18665.	0.8	2
67	Abstract LB-B03: Exosome-based Detection ofEGFR790M in Plasma from Non-Small Cell Lung Cancer Patients. , 2018, , .		0
68	A Rare Case of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia. <i>Cureus</i> , 2018, 10, e2525.	0.2	2
69	RNA-Seq data analysis to identify enriched metabolic pathways and a prognostic signature in squamous cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24288-e24288.	0.8	0
70	Selection of highly stable genes for the transcriptomic evaluation of lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24318-e24318.	0.8	0
71	In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies. <i>Scientific Reports</i> , 2017, 7, 1526.	1.6	60
72	The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche. <i>Cancer Letters</i> , 2017, 402, 43-51.	3.2	36

#	ARTICLE	IF	CITATIONS
73	P2.03b-039 Cell-Free (cf) DNA and cfRNA levels in Plasma of Lung Cancer Patients Indicate Disease Status and Predict Progression. <i>Journal of Thoracic Oncology</i> , 2017, 12, S959.	0.5	2
74	Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found. <i>ESMO Open</i> , 2017, 2, e000162.	2.0	19
75	New targets bring hope in squamous cell lung cancer: neurotrophic tyrosine kinase gene fusions. <i>Laboratory Investigation</i> , 2017, 97, 1268-1270.	1.7	20
76	Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping. <i>Journal of Thoracic Oncology</i> , 2017, 12, e89-e90.	0.5	34
77	Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America. <i>Clinical Lung Cancer</i> , 2017, 18, e71-e79.	1.1	23
78	Ceritinib: an orphan drug for ALK positive non-small cell lung cancer with robust clinical evidence. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 991-997.	0.5	0
79	Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib. <i>Frontiers in Medicine</i> , 2017, 4, 13.	1.2	13
80	Correlation of cell-free circulating DNA, RNA, and PD-L1 from plasma with clinical response in patients with metastatic lung and breast cancers. <i>Journal of Clinical Oncology</i> , 2017, 35, 11550-11550.	0.8	1
81	Gender and health care outcomes in patients with non-small cell lung cancer: A meta-analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, e18113-e18113.	0.8	0
82	Impressive Response to Concomitant Platinum-based Chemotherapy and Yttrium-90 in a Patient with Heavily Pretreated Triple-negative Breast Cancer Widely Metastasized to the Liver. <i>Cureus</i> , 2017, 9, e1402.	0.2	0
83	Neurotrophic tyrosine kinase gene fusions: another opportunity for targeting in lung cancer. <i>Lung Cancer Management</i> , 2016, 5, 1-4.	1.5	1
84	Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. <i>ESMO Open</i> , 2016, 1, e000055.	2.0	28
85	3PD Liquid biopsy in patients with adenocarcinoma of the lung and its correlation with their tumor tissue molecular profile. <i>Journal of Thoracic Oncology</i> , 2016, 11, S58.	0.5	1
86	BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 101, 32-39.	2.0	15
87	P1.13 (also presented as PD2.01): Lung Cancer Chromosomal Aberrations and Gene Expression Profiles of Hispanics Living in the US or Latin America are Similar. <i>Journal of Thoracic Oncology</i> , 2016, 11, S187-S188.	0.5	0
88	P1.29: "Real World" Use of Liquid Biopsy in Patients With Lung Adenocarcinoma and Correlation With Tumor Tissue Genetic Profile. <i>Journal of Thoracic Oncology</i> , 2016, 11, S199-S200.	0.5	0
89	PD2.01 (also presented as P1.13): Lung Cancer Chromosomal Aberrations and Gene Expression Profiles of Hispanics Living in the US or Latin America are Similar. <i>Journal of Thoracic Oncology</i> , 2016, 11, S176.	0.5	5
90	The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 385-392.	1.9	26

#	ARTICLE	IF	CITATIONS
91	Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing. <i>Clinical Cancer Research</i> , 2016, 22, 3281-3285.	3.2	33
92	Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9017-9017.	0.8	129
93	Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23101-e23101.	0.8	1
94	Making steps to decrease emergency room visits in patients with cancer: Our experience after participating in the ASCO Quality Training Program.. <i>Journal of Clinical Oncology</i> , 2016, 34, 51-51.	0.8	2
95	Are the gene expression profiles of Hispanic patients with lung cancer living in the US different from Hispanics living abroad?. <i>Journal of Clinical Oncology</i> , 2016, 34, e18059-e18059.	0.8	0
96	Reducing unnecessary tests in oncology patients using best practice advisories in the Electronic Medical Record.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18239-e18239.	0.8	0
97	Checkpoints inhibitors in first line therapy of metastatic non-small cell lung cancer patients. <i>Translational Cancer Research</i> , 2016, 5, S1443-S1448.	0.4	0
98	cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. <i>Cancers</i> , 2015, 7, 556-573.	1.7	33
99	Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1101-1109.	1.9	37
100	Nintedanib in non-small cell lung cancer: from preclinical to approval. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 164-172.	1.0	28
101	Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1493-1500.	1.9	117
102	Preliminary considerations on the use of nintedanib (BIBF 1120) in lung cancer patients. <i>Lung Cancer Management</i> , 2014, 3, 123-126.	1.5	0
103	Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines. <i>Current Oncology Reports</i> , 2014, 16, 400.	1.8	27
104	Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1173-1187.	1.1	25
105	Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2735-2743.	0.8	458
106	Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 15-26.	1.4	17
107	Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation. <i>Lung Cancer</i> , 2014, 84, 110-115.	0.9	41
108	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. <i>Cancer Treatment Reviews</i> , 2014, 40, 990-1004.	3.4	70

#	ARTICLE	IF	CITATIONS
109	Early-stage non-small-cell lung cancer: overview of adjuvant chemotherapy and promising advances. <i>Lung Cancer Management</i> , 2014, 3, 85-99.	1.5	0
110	The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?. <i>Current Drug Targets</i> , 2014, 15, 1284-1292.	1.0	10
111	ALK and crizotinib: after the honeymoon what else? Resistance mechanisms and new therapies to overcome it. <i>Translational Lung Cancer Research</i> , 2014, 3, 250-61.	1.3	44
112	A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 523-530.	1.1	362
113	Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1065-1072.	1.1	7
114	A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC). <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1103-1110.	1.1	7
115	A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 81, 416-421.	0.9	21
116	BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1081-1088.	1.9	28
117	Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1415-1421.	0.8	180
118	Targeting angiogenesis in non-small-cell lung cancer: a focus on current approaches and future developments. <i>Clinical Practice (London, England)</i> , 2013, 10, 503-517.	0.1	0
119	Therapeutic vaccines in non-small cell lung cancer. <i>ImmunoTargets and Therapy</i> , 2013, 2, 115.	2.7	5
120	Current Algorithm for Treatment of Advanced NSCLC Patients: How to Include Active Immunotherapy?. <i>Journal of Cancer Therapy</i> , 2013, 04, 59-75.	0.1	1
121	Epidermal growth factor vaccine in non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 439-445.	1.1	9
122	Targeting the Met pathway in lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 519-528.	1.1	27
123	Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2012, 48, 887-892.	0.8	42
124	Emerging role of multikinase inhibitors for refractory thyroid cancer. <i>Biologics: Targets and Therapy</i> , 2012, 6, 257.	3.0	9
125	Novel molecular targeted therapies for refractory thyroid cancer. <i>Head and Neck</i> , 2012, 34, 736-745.	0.9	23
126	A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors. <i>Cancer</i> , 2012, 118, 4262-4270.	2.0	23

#	ARTICLE	IF	CITATIONS
127	Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. <i>Investigational New Drugs</i> , 2012, 30, 1261-1269.	1.2	21
128	Immunotherapy for nonsmall-cell lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 90-93.	0.3	3
129	Active immunotherapy for non-small-cell lung cancer: moving toward a reality. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1599-1605.	1.1	7
130	Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of literature. <i>Journal of Medical Case Reports</i> , 2011, 5, 483.	0.4	15
131	Development of targeted therapy for squamous cell carcinomas of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 373-386.	1.1	9
132	Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1140-1145.	0.8	112
133	Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 43-54.	0.2	53
134	The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-10.	3.0	31
135	A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1054-1059.	0.5	84
136	Efficacy and Toxicity of Chemoradiotherapy with Carboplatin and Irinotecan Followed by Consolidation Docetaxel for Unresectable Stage III Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 533-539.	0.5	17
137	Nasopharyngeal carcinoma: alternative treatment options after disease progression. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 377-386.	1.1	16
138	EGF receptor in lung cancer: a successful story of targeted therapy. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1577-1587.	1.1	12
139	Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 549-557.	1.1	1
140	Oxaliplatin in First-line Therapy for Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 18-24.	1.1	36
141	Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art. <i>Seminars in Immunology</i> , 2010, 22, 105-112.	2.7	44
142	Developing a Vaccine for Non-Small-Cell Lung Cancer. <i>Postgraduate Medicine</i> , 2009, 121, 187-189.	0.9	1
143	How is gene-expression profiling going to challenge the future management of lung cancer?. <i>Future Oncology</i> , 2009, 5, 827-835.	1.1	8
144	Cancer vaccines: a new therapeutic alternative for lung cancer therapy?. <i>Immunotherapy</i> , 2009, 1, 727-728.	1.0	0

#	ARTICLE	IF	CITATIONS
145	Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. <i>Annals of Oncology</i> , 2009, 20, 921-927.	0.6	134
146	Second-Line Therapy for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2009, 10, 91-98.	1.1	5
147	Gene Expression Profiling and Non-Small-Cell Lung Cancer: Where Are We Now?. <i>Clinical Lung Cancer</i> , 2009, 10, 168-173.	1.1	18
148	Radiation technique influence on percutaneous endoscopic gastrostomy tube dependence: Comparison between two radiation schemes. <i>Head and Neck</i> , 2009, 31, 944-948.	0.9	6
149	Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: present and future. <i>Oncology Reviews</i> , 2009, 3, 137-148.	0.8	1
150	Abstract B206: Pharmacokinetic and pharmacodynamic analysis of patients treated with the histone deacetylase inhibitor entinostat in combination with erlotinib. , 2009, , .		0
151	Controversies in the management of stage IIIA non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1913-1929.	1.1	5
152	Targeting important pathways in head and neck cancer: from the bench to the clinic. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1819-1835.	1.1	2
153	Efficacy and Safety of Oxaliplatin and Gemcitabine with Bevacizumab in Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 511-515.	0.5	24
154	Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 1705-1715.	13.9	1,537
155	New targets for non-small-cell lung cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1423-1437.	1.1	35
156	Allogeneic tumor-cell-based vaccines secreting endoplasmic reticulum chaperone gp96. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1679-1688.	1.4	15
157	EGFR Targeting of Solid Tumors. <i>Cancer Control</i> , 2007, 14, 295-304.	0.7	245
158	M17-01: Immunotherapy for lung tumors. <i>Journal of Thoracic Oncology</i> , 2007, 2, S197-S198.	0.5	0
159	Intensity-Modulated Radiotherapy With Concurrent Chemotherapy for Previously Irradiated, Recurrent Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1067-1073.	0.4	80
160	Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2453-2476.	0.6	13
161	Heat Shock Protein-Based Cancer Vaccines. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 637-659.	0.9	17
162	Advantage of EUS Trucut biopsy combined with fine-needle aspiration without immediate on-site cytopathologic examination. <i>Gastrointestinal Endoscopy</i> , 2006, 64, 505-511.	0.5	109

#	ARTICLE	IF	CITATIONS
163	Does EUS Trucut Biopsy (TCB) Plus Fine Needle Aspiration (FNA) Increase Accuracy Over FNA in Thoracic Disease When No On-Site Cytopathologist Is Present?. <i>Gastrointestinal Endoscopy</i> , 2006, 63, AB276.	0.5	0
164	Pemetrexed-associated urticarial vasculitis. <i>Lung Cancer</i> , 2006, 51, 247-249.	0.9	31
165	Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2006, 53, 347-353.	0.9	19
166	New developments in chemotherapy for advanced non-small cell lung cancer. <i>Current Opinion in Internal Medicine</i> , 2006, 5, 305-310.	1.5	15
167	Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. <i>Liver International</i> , 2006, 26, 625-629.	1.9	58
168	Present and future of lung cancer vaccines. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 445-459.	1.0	8
169	Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 5025-5033.	0.8	154
170	Induction chemotherapy in the management of squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1205-1215.	1.1	11
171	Combined modality therapy for limited-disease small cell lung cancer. <i>Current Treatment Options in Oncology</i> , 2005, 6, 69-74.	1.3	8
172	DNA methylation: its role in lung carcinogenesis and therapeutic implications. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 667-679.	1.1	3
173	Clinical Responses to Gefinitib After Failure of Treatment With Cetuximab in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 4244-4245.	0.8	10
174	Lung Cancer Immunotherapy. <i>Clinical Medicine and Research</i> , 2005, 3, 221-228.	0.4	58
175	Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2005, 46, 297-298.	0.6	2
176	Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 635-644.	1.1	9
177	Allogeneic Vaccination With a B7.1 HLA-A Gene-Modified Adenocarcinoma Cell Line in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 2800-2807.	0.8	103
178	Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer—experience from a prematurely closed phase II study. <i>Lung Cancer</i> , 2004, 45, 131-132.	0.9	8
179	The Utility of a Bone Marrow Biopsy in Diagnosing the Source of Fever of Unknown Origin in Patients With AIDS. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 37, 1599-1603.	0.9	14
180	Chemotherapy for advanced non-small-cell lung cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2004, 2, 173-8.	0.3	21

#	ARTICLE	IF	CITATIONS
181	Induction of CD8 T-cell-Ifn- γ response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. <i>Cancer Gene Therapy</i> , 2003, 10, 850-858.	2.2	27
182	Primary Hepatic Non-Hodgkin's Lymphomas: Case Report and Review of The Literature. <i>American Journal of Gastroenterology</i> , 2003, 98, 2789-2793.	0.2	49
183	Radical Resection of Periampullary Tumors in the Elderly: Evaluation of Long-term Results. <i>World Journal of Surgery</i> , 2000, 24, 353-358.	0.8	73
184	Treatment of AIDS-Related Primary Central Nervous System Lymphoma with Zidovudine, Ganciclovir, and Interleukin 2. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 713-719.	0.5	89
185	Pulmonary Bone Marrow Embolism in Sickle Cell Disease. <i>Southern Medical Journal</i> , 1999, 92, 245-247.	0.3	13
186	Successful treatment of lymphomatoid granulomatosis using cyclosporin-A after failure of intensive chemotherapy. , 1996, 53, 192-195.		6
187	Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP). <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4